MedTrace Logo

Combined Therapy for Hepatocellular Carcinoma >3-<5 cm

NCT04721470 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 278

Last updated 2021-01-22

No results posted yet for this study

Summary

The purpose of this study is to compare the safety and efficacy of combined therapy with conventional transarterial chemoembolization (cTACE) + microwave ablation (MWA) versus only TACE or MWA for treatment of hepatocellular carcinoma (HCC) \>3-\<5 cm.

Conditions

Interventions

PROCEDURE

Combined therapy

Patients undergoing combined therapy

PROCEDURE

Microwave ablation

Patients undergoing Microwave ablation

PROCEDURE

Transarterial chemoembolization

Patients undergoing Transarterial chemoembolization

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Principal Investigators

  • Mohammad A Basha, Professor · Zagazig University, Egypt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2020-05-15
Completion
2020-10-20

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04721470 on ClinicalTrials.gov